Clinical trial
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's…
NCT00387270 · Medivation, Inc., Industry · Completed
Key facts
| NCT number | NCT00387270 |
|---|---|
| Title | Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease |
| Official title | A Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease |
| Lead sponsor | Medivation, Inc., Industry |
| Collaborators | Huntington Study Group |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Huntington's Disease |
| Intervention type | Drug |
| Interventions | Dimebon |
| Enrollment | 9 |
| Start date | Oct 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Oct 12, 2006 |
| Last update posted | Jan 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: